ライフサイエンスコーパス: aminocaproic acid

1 olling the concentration of the initiator (6-aminocaproic acid).

2 pients of aprotinin than among recipients of aminocaproic acid.

3 of benzenesulfonic acid and 45 mmol L(-1) of aminocaproic acid.

4 responds well to outpatient care and topical aminocaproic acid.

5 ous iron, erythropoietin, G-CSF, and epsilon aminocaproic acid.

6 rotein, and binding was inhibited by epsilon-aminocaproic acid.

7 absence and presence of the ligand, epsilon-aminocaproic acid.

8 This process is inhibited by epsilon-aminocaproic acid.

9 ce can be reduced by the presence of epsilon-aminocaproic acid.

10 analysis based on an electrolyte of epsilon-aminocaproic acid.

11 idence interval, 1.19-1.85), whereas neither aminocaproic acid (132 deaths among 834 patients [15.8%]

12 t reduction in total blood loss over epsilon-aminocaproic acid (-184 mL; 95% CI, -256 to -112) and tr

13 ytic agents such as tranexamic acid, epsilon-aminocaproic acid, 4-aminomethylbenzoic acid, and aproti

14 or the use of aprotinin (33,517 patients) or aminocaproic acid (44,682 patients) on the day CABG was

15 Adipic acid (AA), 6-aminocaproic acid (6-ACA) and 1,6-hexamethylenediamine (

16 This is applied to a 6-aminocaproic acid (6-ACA) pathway in Escherichia coli co

17 otal postoperative transfusions with epsilon-aminocaproic acid (61% reduction versus placebo, P<0.010

18 butyric acid, 5-aminopentanoic acid, epsilon-aminocaproic acid, 7-aminoheptanoic acid, and t-4-aminom

19 sed three agents (aprotinin [1295 patients], aminocaproic acid [883], and tranexamic acid [822]) as c

20 epsilon-Aminocaproic acid, a Lys analogue, effectively blocks an

21 directed against t-PA and u-PA, and epsilon-aminocaproic acid, a lysine analog that inhibits Plg act

22 745,870, a dopamine receptor antagonist, and aminocaproic acid, a protease inhibitor that reduce drus

23 tandard dipeptide with a linker derived from aminocaproic acid (Aca).

24 a modified method that involves N-acryloyl-6-aminocaproic acid (ACA).

25 the reductions in IL-6 and IL-10 by epsilon-aminocaproic acid achieved statistical significance.

26 higher mortality than patients who received aminocaproic acid alone.

27 er animal plasma in the presence of epsilon -aminocaproic acid, an active-site inhibitor that stabili

28 ve hemorrhage after cardiac surgery, epsilon-aminocaproic acid, an alternative antifibrinolytic, is c

29 epsilon-Aminocaproic acid and aprotinin had no effect on risks o

30 Both the lysine analog epsilon-aminocaproic acid and L-proline inhibited the binding of

31 reductions in total blood loss with epsilon-aminocaproic acid and low-dose aprotinin (each with a 35

32 rast, the less expensive generic medications aminocaproic acid and tranexamic acid are safe alternati

33 Both epsilon-aminocaproic acid and tranexamic acid inhibit clot disso

34 e safer and less expensive alternatives (ie, aminocaproic acid and tranexamic acid) are available.

35 to use of 2 lysine analog antifibrinolytics (aminocaproic acid and tranexamic acid), the serine prote

36 Fibrinolysis inhibitors, including epsilon-aminocaproic acid and tranexamic acid, were effective in

37 ed aprotinin, 6776 patients (66.8%) received aminocaproic acid, and 2029 patients (20.0%) received no

38 e colony-stimulating factor, erythropoietin, aminocaproic acid, and phytonadione was administered.

39 meta-analysis to compare aprotinin, epsilon-aminocaproic acid, and tranexamic acid with placebo and

40 Aprotinin but not epsilon-aminocaproic acid appears to attenuate the rise in the p

41 ntrate, recombinant factor VIIa, and epsilon-aminocaproic acid, as potential therapeutic options.

42 mice with the fibrinolytic inhibitor epsilon-aminocaproic acid before endotoxin increased both the nu

43 The plasminogen-specific inhibitor epsilon-aminocaproic acid blocked the tv-rENO1-plasminogen assoc

44 The lysine analog epsilon-aminocaproic acid blocks Plm-catalyzed BK generation.

45 [Lys3]Bombesin ([Lys3]BBN) and aminocaproic acid-bombesin(7-14) (Aca-BBN(7-14)) were la

46 antiserum, by low concentrations of epsilon-aminocaproic acid, by methylation of lysine residues in

47 Both aprotinin and epsilon-aminocaproic acid decreased blood loss compared with sal

48 hese data suggest that aprotinin and epsilon-aminocaproic acid differ in their effects on the inflamm

49 ifibrinolytic medication (tranexamic acid or aminocaproic acid) during the bleeding event.

50 plasminogen (Klpg) with the ligands epsilon-aminocaproic acid (EACA) and trans-4-(aminomethyl)cycloh

51 ytic drugs tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA) are structurally similar to the

52 atient received a loading dose of 5 grams of aminocaproic acid (EACA) intravenously 3 hours prior to

53 E) method containing high amounts of epsilon-aminocaproic acid (EACA) provides a detailed and robust

54 The binding constants of epsilon-aminocaproic acid (EACA), 7-aminoheptanoic acid (7-AHpA)

55 ibited plasminogen activation, e.g., epsilon-aminocaproic acid (EACA), or plasminogen antiserum.

56 Treatment with epsilon-aminocaproic acid (EACA), which inhibits plasmin activat

57 nhibited by lysine analogues such as epsilon-aminocaproic acid (EACA).

58 riant) in its unliganded and ligand [epsilon-aminocaproic acid (EACA)] bound modes and the structure

59 The binding is inhibited by epsilon-aminocaproic acid (epsilonACA), indicating the requireme

60 In contrast, epsilon-aminocaproic acid, fibrin, and fibrinogen, which induce

61 4% higher in the aprotinin group than in the aminocaproic acid group (relative risk, 1.64; 95% confid

62 inolytic drugs such as aprotinin and epsilon-aminocaproic acid have been effective in reducing fibrin

63 sion inasmuch as tranexamic acid and epsilon-aminocaproic acid inhibited cell adhesion.

64 and the presence of a lysine analog, epsilon-aminocaproic acid, inhibited the ErpP-plasminogen intera

65 ies, the considerably less-expensive epsilon-aminocaproic acid may be preferred over aprotinin for re

66 n 1985 and 1998 involving the use of epsilon-aminocaproic acid (n=9) or aprotinin (n=46) in patients

67 vent (n = 54 unique subjects; n = 18 epsilon aminocaproic acid, n = 35 tranexamic acid, and n = 1 bot

68 Neither aminocaproic acid nor tranexamic acid was associated wit

69 xamined the effects of aprotinin and epsilon-aminocaproic acid on plasma levels of proinflammatory [i

70 The presence of epsilon-aminocaproic acid only slightly inhibited binding of apo

71 is by the indirect plasmin inhibitor epsilon-aminocaproic acid or by alpha2AP restored thrombosis in

72 As compared with the use of aminocaproic acid or no antifibrinolytic agent, aprotini

73 um creatinine levels than those who received aminocaproic acid or no antifibrinolytic agent.

74 ransfused was similarly reduced with epsilon-aminocaproic acid (OR, 0.32; 95% CI, 0.15 to 0.69) and h

75 tudy to receive high-dose aprotinin, epsilon-aminocaproic acid, or saline placebo.

76 ) for the comparison with patients receiving aminocaproic acid (P=0.004).

77 nin recipients (4.5%) and 1101 of the 44,682 aminocaproic acid recipients (2.5%) died.

78 Saturating levels of epsilon-aminocaproic acid reduced the affinity of SK for labeled

79 Pretreatment with the lysine analog, e-aminocaproic acid, significantly increased platelet-deri

80 activation by CRT were inhibited by epsilon-aminocaproic acid, suggesting that an internal lysine re

81 nificantly inhibited by the lysine analog xi-aminocaproic acid, suggesting that the lysine-binding si

82 from human serum in the presence of epsilon -aminocaproic acid was also developed.

83 Aminocaproic acid was not statistically associated with

84 fewer data are available for tranexamic and aminocaproic acid, we support their use as alternatives

85 hyl)cadaverdine, but not N6-(1-iminoethyl)-6-aminocaproic acid, were NADPH-dependent, irreversible in

86 -4-Cpa-Gln-D-Phe-Pro-Asp-Aca) (Aca = epsilon-aminocaproic acid), which did not contain tyrosine, was

87 in the presence of the lysine analog epsilon-aminocaproic acid, which precludes apo(a)-B100 associati